

# SECURITIES AND EXCHANGE COMMISSION

## FORM 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: **2007-12-04** | Period of Report: **2007-12-03**  
SEC Accession No. **0001167379-07-000113**

([HTML Version](#) on [secdatabase.com](#))

### FILER

#### ALCON INC

CIK: **1167379** | IRS No.: **980205094** | State of Incorporation: **V8** | Fiscal Year End: **1231**  
Type: **6-K** | Act: **34** | File No.: **001-31269** | Film No.: **071283540**  
SIC: **3851** Ophthalmic goods

Mailing Address	Business Address
<i>BOSCH 69 6331 HUNENBERG SWITZERLAND V8 0000</i>	<i>6201 SOUTH FREEWAY FORT WORTH TX 76134 8175686248</i>

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE  
ACT OF 1934**

For the month of **December 2007**

Commission File Number 001-31269

**ALCON, INC.**

(Translation of registrant's name into English)

Bösch 69  
P.O. Box 62  
6331 Hünenberg, Switzerland  
41-41-785-8888

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): \_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): \_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- \_\_\_\_\_

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Alcon, Inc.**

(Registrant)

Date December 3, 2007

By /s/ Joanne Beck

Name: Joanne Beck

Title: General Manager

Date December 3, 2007

By /s/ Stefan Basler

Name: Stefan Basler

Title: Attorney-in-Fact





## **Alcon Receives FDA Approval of TRIESENCE™ Injectable Triamcinolone Suspension for Use in Eye Surgery**

**HUENENBERG**, Switzerland - November 30, 2007 - Alcon (NYSE:ACL) announced today that the United States Food and Drug Administration (FDA) has approved TRIESENCE™ (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid for visualization during vitrectomy and treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

The active ingredient in TRIESENCE™, triamcinolone acetonide, has been used for many years to treat retinal disease. This new approval brings ophthalmologists a sterile, preservative-free formulation of the compound specifically developed for use in the eye to treat various retinal inflammatory conditions.

### About TRIESENCE™

TRIESENCE™ injectable suspension is a synthetic corticosteroid indicated for treatment of the following ophthalmic diseases: sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. TRIESENCE™ is also indicated for visualization during vitrectomy. For complete product information, see product insert.

### About Eye Inflammation

Eye inflammation most commonly occurs in response to infection, allergy, surgery or trauma (i.e., blow to the eye, foreign body, chemical injury). Uveitis, one form of eye inflammation treatable with TRIESENCE™, is one of the more common types of inflammation. With uveitis, the uveal tract of the eye, including the iris, the ciliary body and the choroid, becomes inflamed. This can result from ocular trauma or an existing systemic disease. In typical uveitis the patient experiences eye pain, photophobia and excessive tearing. Sufferers report a deep, dull aching of the eye and surrounding area. While haziness may be present, visual acuity is not usually impaired to any great extent.

### About Vitrectomy

Vitrectomy is a type of eye surgery in which some or all of the vitreous humor is removed from the eye. This type of surgery is often performed in patients with diabetic retinopathy, a detached retina, a macular hole or other conditions. TRIESENCE™ assists retinal surgeons with visualization during these types of surgery.

### About Alcon

Alcon, Inc. is the world's leading eye care company, with sales of approximately \$4.9 billion in 2006. Alcon, which has been dedicated to the ophthalmic industry for 60 years, researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens care solutions and other vision care products that treat diseases,

disorders and other conditions of the eye. Alcon's majority shareholder is Nestle, S.A., the world's largest food company. For more information on Alcon Inc., visit the company's web site at [www.alcon.com](http://www.alcon.com).

###

Caution Concerning Forward-Looking Statements. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements. These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. You should read this press release with the understanding that our actual future results may be materially different from what we expect. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

For information, contact:  
Holly Clark (Strategic Corporate Communications)  
817-551-8696  
[holly.clark@alconlabs.com](mailto:holly.clark@alconlabs.com)

[www.alcon.com](http://www.alcon.com)  
SOURCE: Alcon, Inc.